Biomarkers of vascular injury in relation to myocardial infarction risk: A population-based study

Laura Pletsch-Borba1,2, Mirja Grafestätter1,2, Anika Hüsing1, Sandra González Maldonado3, Manja Kloss1, Marie-Luise Groß1, Theron Johnson1, Disorn Sookthai1, Peter Bugert4, Rudolf Kaaks4 & Tilman Kühn1

Little is known about circulating biomarkers of vascular injury in relation to cardiovascular disease risk. Thus, we evaluated associations between six novel markers (E-Selectin, P-Selectin, thrombomodulin, thrombopoietin, intercellular adhesion molecule 3 and GPIIb/IIIa) and established cardiovascular risk factors as well as the risk of myocardial infarction (MI) in a population-based study. Biomarkers were measured in pre-diagnostic plasma samples of a case-cohort subset of EPIC-Heidelberg (incident MI cases: n = 369, random sub-cohort: n = 2,418). Generalized Linear models were used to analyse cross-sectional associations between biomarkers and cardiovascular risk factors. Multivariable Cox Regression analyses were carried out to obtain Hazard Ratios (HRs) of MI across quartiles of biomarkers levels. Cross-sectional analyses showed that sex, smoking, alcohol consumption, diabetes and exogenous hormone use were associated with biomarker levels. However, while fibrinogen was associated with MI risk (HR per standard deviation: 2.97 [95% confidence interval: 1.61, 5.46]), none of the six novel biomarkers was associated with MI risk after multivariable adjustment. In a population-based cohort, biomarkers of vascular injury were associated with established cardiovascular risk factors, but not MI risk. The tested biomarkers may reflect pathophysiological alterations in cardiovascular disease development rather than constituting independent MI risk factors.

Myocardial infarction (MI), the most common cardiovascular cause of death, is driven by atherosclerosis1. Vascular injury, one of the hallmarks of atherosclerosis, is mediated by complex interactions between the endothelium, activated platelets and immune cells that involve a plethora of signalling molecules such as inflammatory cytokines, growth factors, adhesion molecules, and coagulation factors2–4. While biomarkers of inflammation and coagulation have been assessed in large-scale epidemiological studies in relation to incident MI5–7, surprisingly little is known about platelet-derived signalling molecules and adhesion factors as potential biomarkers of MI risk4.

For the present prospective study on MI risk, we selected the following six circulating factors implicated in vascular injury and primary haemostasis as candidate biomarkers of MI risk: E-Selectin, P-Selectin, thrombomodulin (TM), thrombopoietin (TPO), intercellular adhesion molecule 3 (ICAM3), and glycoprotein IIb/IIIa (GPIIb/IIIa). Higher circulating levels of E-Selectin (mediating immune cell adhesion to the endothelium) and P-Selectin (mediating platelet adhesion) have been related to atherosclerosis and thrombosis8–10. GPIIb/IIIa is a receptor expressed on the surface of activated platelets, essential for platelet aggregation via binding to fibrinogen11. The molecule is a target in the treatment of acute coronary syndromes by GPIIb/IIIa inhibitors, but its platelet-derived circulating form has not been evaluated in large-scale epidemiological studies12. TM is a membrane glycoprotein expressed by endothelial cells that converts thrombin from a procoagulant to an anticoagulant enzyme, thus modulating platelet activation and haemostasis13. TPO is a humoral substance produced by the liver responsible for stimulating platelet production14. As a circulating biomarker, it has been shown to be inversely associated with biomarkers of platelet turnover15. Finally, ICAM3 is an integrin that may mediate interactions between leucocytes and endothelial cells in atherosclerosis16,17.

1Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 2Medical Faculty, University of Heidelberg, Heidelberg, Germany. 3Department of Neurology, University of Heidelberg, Heidelberg, Germany. 4Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, and German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany. Correspondence and requests for materials should be addressed to T.K. (email: t.kuehn@dkfz.de)
Given the lack of epidemiological studies on the above-mentioned plasma markers, we used the population-based EPIC-Heidelberg cohort to evaluate associations (a) between the markers and established cardiovascular risk factors in cross-sectional analyses, and (b) between the markers and MI risk in prospective analyses. In addition, we carried out mediation analyses to investigate whether relationships between established cardiovascular risk factors and MI risk could be mediated by the proposed biomarkers.

**Results**

**Characteristics of the study population.** Median baseline age in the sub-cohort was 51.0 (IQR 14.1) years, and 53% were women, while among MI cases mean age was 56.7 (IQR 10.1) years, and 22% were women. Baseline values for cardiovascular risk factors and biomarkers among cases and in the sub-cohort are reported in Table 1. Median follow-up of the sub-cohort and the MI cases was respectively 9.8 (IQR 1.9) and 6.1 (IQR 4.6) years. Cases showed a worse cardiovascular risk profile than the participants in the sub-cohort. Aspirin use was reported by 7.0% of the cases and 3.4% of the individuals in the sub-cohort. The prevalence of antithrombotic medication use beyond aspirin at baseline was 0.5% among cases and 0.4% in the sub-cohort.

|                                | MI Cases Total (n = 369) | Women (n = 1293, 53%) | Men (n = 1125, 47%) | Total (n = 2418) |
|--------------------------------|--------------------------|-----------------------|---------------------|------------------|
| **Age at recruitment (years)** | 56.7 (10.1)              | 48.59 (15.4)          | 53.05 (11.8)        | 51.03 (14.1)     |
| **Age at diagnosis of MI (years)** | 60.6 (10.6)              | 58.7 (15.0)           | 62.6 (12.2)         | 60.6 (13.6)      |
| **Hypertension (yes)**         | 165 (44.7%)              | 303 (23.4%)           | 375 (33.3%)         | 678 (28.0%)      |
| **Antihypertensive drug use (yes)** | 137 (37.1%)              | 253 (19.6%)           | 279 (24.8%)         | 552 (22.0%)      |
| **Diabetes mellitus (yes)**    | 65 (17.6%)               | 28 (2.2%)             | 64 (5.7%)           | 92 (3.8%)        |
| **Body mass index (kg/m²)**    | 27.6 (5.5)               | 24.3 (5.9)            | 26.3 (4.6)          | 25.5 (5.5)       |
| **Height (cm)**                | 172.2 (12.8)             | 163.6 (8.3)           | 175.9 (8.4)         | 169 (12.8)       |
| **Weight (kg)**                | 82.1 (19.9)              | 65.5 (16.1)           | 81.8 (8.4)          | 74.9 (19.9)      |
| **Waist circumference (cm)**   | 96.7 (19.5)              | 79 (16.0)             | 94.7 (13.5)         | 88 (19.5)        |
| **Alcohol intake at Baseline (g/day)** | 10.6 (21.6)            | 4.3 (8.1)             | 19.7 (29.4)         | 10.2 (21.6)      |
| **Education level**            |                          |                       |                     |                  |
| **Primary School**             | 153 (41.5%)              | 350 (27.1%)           | 334 (29.7%)         | 684 (28.3%)      |
| **Secondary School**           | 130 (35.2%)              | 625 (48.3%)           | 363 (32.3%)         | 988 (40.9%)      |
| **University Degree**          | 86 (23.3%)               | 318 (24.6%)           | 428 (38.0%)         | 746 (30.9%)      |
| **Smoking Status**             |                          |                       |                     |                  |
| **Never**                      | 122 (33.1%)              | 657 (58.4%)           | 381 (33.9%)         | 1038 (42.9%)     |
| **Former, stopped <10 yrs ago** | 77 (20.9%)              | 234 (20.8%)           | 314 (27.9%)         | 548 (22.7%)      |
| **Former, stopped ≥10 yrs ago** | 36 (9.8%)               | 131 (11.6%)           | 131 (11.6%)         | 266 (11.0%)      |
| **Current less than 15 cigarettes/day** | 60 (16.3%)             | 175 (15.6%)           | 175 (15.6%)         | 312 (12.9%)      |
| **Current ≥15 cigarettes/day** | 74 (20.1%)               | 96 (8.5%)             | 96 (8.5%)           | 254 (10.5%)      |
| **Aspirin use (yes)**          | 26 (7.1%)                | 32 (2.5%)             | 49 (4.4%)           | 81 (3.4%)        |
| **Antithrombotic drug use (yes)** | 2 (0.5%)               | 7 (0.5%)              | 2 (0.2%)            | 9 (0.4%)         |
| **Physical Activity**          |                          |                       |                     |                  |
| **Inactive/moderately inactive** | 185 (50.1%)             | 623 (48.2%)           | 503 (44.7%)         | 1126 (46.6%)     |
| **Moderately active/active**   | 184 (49.9%)              | 670 (51.2%)           | 622 (55.3%)         | 1292 (53.4%)     |
| **CRP (mg/l)**                 | 2.0 (2.9)                | 0.95 (2.0)            | 1.1 (2.1)           | 0.99 (2.1)       |
| **LDL (mmol/l)**               | 4.5 (1.4)                | 3.8 (1.4)             | 4.1 (1.3)           | 4.0 (1.4)        |
| **Triglycerides (mmol/l)**     | 2.3 (1.9)                | 1.3 (1.0)             | 1.9 (1.4)           | 1.6 (1.2)        |
| **HDL (mmol/l)**               | 1.2 (0.4)                | 1.6 (0.6)             | 1.2 (0.5)           | 1.4 (0.6)        |
| **Total Cholesterol (mmol/l)** | 6.2 (1.4)                | 5.8 (1.4)             | 5.8 (1.4)           | 5.8 (1.4)        |
| **Fibrinogen (µg/ml)**         | 4050.8 (933.6)           | 3783.4 (893.9)        | 3759.6 (849.0)      | 3775.3 (876.3)   |
| **E-Selectin (ng/ml)**         | 11.2 (6.6)               | 9.2 (5.7)             | 11.1 (6.6)          | 9.9 (6.4)        |
| **P-Selectin (ng/ml)**         | 30.6 (13.5)              | 25.7 (11.2)           | 30.2 (13.2)         | 27.5 (12.4)      |
| **Thrombomodulin (ng/ml)**     | 3.0 (0.9)                | 2.7 (0.9)             | 3.06 (1.0)          | 2.9 (1.0)        |
| **Thrombopoietin (pg/ml)**     | 340.3 (125.2)            | 350.1 (125.1)         | 332.4 (117.3)       | 340.4 (122.4)    |
| **ICAM3 (ng/ml)**              | 0.47 (0.19)              | 0.43 (0.19)           | 0.46 (0.20)         | 0.44 (0.19)      |
| **Glycoprotein IIb/IIIa (ng/ml)** | 384.0 (198.3)            | 384.0 (182.3)         | 382.1 (176.3)       | 382.8 (179.5)    |

Table 1. Baseline characteristics of the EPIC-Heidelberg Case-Cohort Sample (1994–1998). Data presented as median (interquartile range) and number (proportion). Antithrombotic drugs excluding aspirin. CRP, C-reactive protein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ICAM3, intercellular adhesion molecule 3.
Cross-sectional associations between biomarkers and cardiovascular risk factors. Figure 1 depicts Spearman’s coefficients (ρ) for correlations among biomarkers. P-Selectin showed correlations with E-Selectin, ICAM3 and TM at Spearman’s coefficients of 0.56, 0.33, and 0.34. E-Selectin showed weak correlations with ICAM3 and TM (p = 0.30 and ρ = 0.27). Supplementary Table 1 show multivariable adjusted cross-sectional associations between biomarkers of vascular injury and established cardiovascular risk factors. Women presented lower levels of E-Selectin, P-Selectin, and TM than men. Smokers had increased levels of P-Selectin. Heavier alcohol drinkers had increased levels of E-Selectin, but lower levels of TM and TPO. Individuals with diabetes at baseline had higher levels of E-Selectin, P-Selectin and ICAM3. Among women, users of oral contraceptives and hormone replacement therapy at baseline revealed lower levels of E-Selectin, P-Selectin, ICAM3, TM, and TPO. A longer duration of oral contraceptives use was inversely associated with TM, while a longer duration of hormone replacement therapy was inversely associated with P-Selectin and E-Selectin levels. As fibrinogen, the established marker of coagulation, was associated with a majority of cardiovascular risk factors, we further adjusted the analyses on E-Selectin, P-Selectin, TM, TPO, ICAM3, and GPIIb/IIIa for fibrinogen. However, adjustment for fibrinogen only led to marginal changes of the described associations (see Supplementary Table 2).

Associations between Biomarkers and Risk of Myocardial Infarction. From the baseline examination of EPIC-Heidelberg (1994–1998) until December 31st 2006, 369 participants experienced a primary MI, out of which 27 (7%) were fatal (death within the 28 subsequent days of the MI). Associations between the biomarkers and MI risk are shown in Fig. 2. P-Selectin was positively associated with MI risk in model 1 (HR highest vs lowest quartile [95% CI]: 1.64 [1.18, 2.28]). However, upon multivariable adjustment, this association was no longer statistically significant (HR 1.14 [0.80, 1.64]). E-Selectin was associated with decreased MI risk after multivariable adjustment (HR per SD log2 E-Selectin [95% CI]: 0.80 [0.65, 0.99]), but not in model 1, and there was a significant association between fibrinogen, the routine marker of coagulation, and MI risk (HR: 2.97 [1.61, 5.46]). TM, TPO, GPIIb/IIIa, and ICAM3 were not significantly associated with MI risk. Interactions between biomarker levels with sex and age were not statistically significant; therefore stratified analyses were not carried out. Further adjustment of the multivariable statistical model for the use of aspirin and other antithrombotic drugs only marginally changed the HRs for MI (data not shown). Sensitivity analyses restricting the follow-up time to the first 5 years after baseline showed highly similar results compared with the main analyses covering the entire follow-up duration (Supplementary Table 3).

Mediation analyses based on the method proposed by VanderWeele18 were conducted for biomarkers with indications of associations with MI risk in model 1 at least, i.e. P-Selectin and fibrinogen (see Table 2). Multivariable analyses did not indicate that associations between lifestyle factors and MI risk were mediated via P-Selectin. By contrast, associations between smoking, alcohol consumption, and BMI and MI risk were partially mediated by plasma levels of fibrinogen (fully adjusted mediated proportions, respectively: 5.7%, p = 0.01; 15.7%, p < 0.001; 24.8%, p < 0.001).
Discussion

In the present study we found that, in a population-based cohort, biomarkers of vascular injury (P-Selectin, E-Selectin, GPIb/IIa, TPO, TM, and ICAM3) were independently associated with several established cardiovascular risk factors. However, in contrast to fibrinogen (the established risk marker of vascular injury and coagulation), none of these biomarkers was significantly associated with MI risk in longitudinal analyses. Mediation analyses did not suggest that associations between established CVD risk factors and MI risk could be mediated by the six biomarkers, whereas they did indicate that fibrinogen partially mediates the associations between smoking, alcohol consumption, and BMI with MI risk. Thus, E-Selectin, P-Selectin, TPO, TM, GPIb/IIa, and ICAM3 may reflect established CVD risk factors rather than constituting independent risk factors for MI.

As stated above, biomarkers of vascular injury showed several associations with cardiovascular risk factors in our cross-sectional analyses, independent of fibrinogen. In line with previous analyses from the KORA Study, our results suggested higher levels of E-Selectin among persons with prevalent diabetes19,20. While a significant inverse association between fibrinogen and incident diabetes was observed in the KORA Study, fibrinogen was neither associated with prevalent diabetes in our study nor in the KORA Study20,21. In our study, prevalent diabetes was significantly associated with increased P-Selectin levels, which is in line with a previous study22, and with ICAM3 levels, which has not been assessed before. The association between P-Selectin and smoking that we report has already been described, although not from multivariable models adjusted for other cardiovascular risk factors and fibrinogen22. Similarly, while a positive association between alcohol consumption and increased E-Selectin levels has been observed before20, we demonstrated that this association is independent of fibrinogen and other cardiovascular risk factors. This observation seems particularly interesting considering that alcohol was inversely associated with fibrinogen in our study - as in many others before23 - but also with GPIb/IIa and TPO, which may explain putative cardio-protective effects of alcohol intake24. Nevertheless, the positive association between alcohol intake and E-Selectin in our analyses suggests that alcohol intake may also induce pro-coagulant haemostatic factors. Such differential effects of alcohol may be one explanation for differential associations between alcohol intake and specific cardiovascular outcomes25. With regard to the use of hormones among women, the associations we found between oral contraceptive use and hormone replacement therapy with lower fibrinogen and E-Selectin levels, respectively, are again in line with previous findings26,28. Exogenous hormone use was further associated with lower levels of P-Selectin, TM, TPO, and ICAM3 in the EPIC-Heidelberg Study, which is consistent with potential anti-thrombotic and vasodilatory effects of exogenous hormones27, although a higher
### Table 2. Direct and indirect (i.e. partially mediated via fibrinogen and P-Selectin) associations between cardiovascular risk factors and incident myocardial infarction.  
- Smoking Status*: Categorized in never smoker, former quitted > 10 y ago, former quitted ≤ 10 y ago, current < 15 cigarettes/day, current ≥ 15 cigarettes/day, and modelled as continuous trend variable.  
- Alcohol Intake*: Categorized in no intake, ≤ 12 g/d, ≥ 12–23.9 g/d, ≥ 24–39.9 g/d, ≥ 40 g/d in the 1-year period previous to the interview, and modelled as continuous trend variable.  
- Hazard Ratios (95% Confidence Intervals) for direct and indirect effects. Model 1 adjusted for age and sex. Model 2 additionally adjusted for height (m), waist circumference (cm), alcohol consumption (g/day), smoking status (never, former quitted > 10 y ago, former quitted ≤ 10 y ago, current < 15 cigarettes/day, current ≥ 15 cigarettes/day), hypertension, antihypertensive drug use, diabetes mellitus, C-Reactive Protein (CRP), total cholesterol, HDL cholesterol, education level, physical activity level and P-Selectin/Fibrinogen when appropriate.

|                                      | Direct effect | Indirect effect | Proportion mediated |
|--------------------------------------|--------------|----------------|---------------------|
|                                      | HR (95%CI)   | P-value        | HR (95%CI)          | P-value |
| **P-Selectin**                       |              |                |                     |         |
| Smoking Status*                      |              |                |                     |         |
| Model 1                              | 1.10(1.06,1.14) | <0.001        | 1.00(0.99,1.01)     | 0.1     | 4.3%          |
| Model 2                              | 1.09(1.05,1.13) | <0.001        | 1.00(0.99,1.01)     | 0.9     | 0.4%          |
| Current Smoking                      |              |                |                     |         |
| Model 1                              | 1.18(1.04,1.33) | <0.01         | 1.01(1.00,1.02)     | 0.049   | 7.7%          |
| Model 2                              | 1.00(0.99,1.00) | 0.1           | 1.00(0.99,1.01)     | 0.7     | 1.5%          |
| Ever Smoking                         |              |                |                     |         |
| Model 1                              | 1.15(1.04,1.15) | <0.01         | 1.01(1.00,1.02)     | 0.04    | 7.9%          |
| Model 2                              | 1.12(1.02,1.24) | 0.02          | 1.00(0.99,1.01)     | 0.7     | 1.7%          |
| Alcohol Intake*                      |              |                |                     |         |
| Model 1                              | 0.96(0.93,0.98) | <0.01         | 1.01(1.01,1.02)     | 0.6     | 0.8%          |
| Model 2                              | 0.96(0.93,0.99) | 0.02          | 1.00(0.99,1.01)     | 0.8     | 0.0%          |
| Prevalent Hypertension               |              |                |                     |         |
| Model 1                              | 1.20(1.09,1.32) | <0.001        | 1.00(0.99,1.01)     | 0.8     | 0.4%          |
| Model 2                              | 1.12(0.96,1.29) | 0.1           | 1.00(0.99,1.01)     | 0.9     | 0.2%          |
| Antihypertensive drug use            |              |                |                     |         |
| Model 1                              | 1.18(1.07,1.29) | <0.01         | 0.99(0.99,1.01)     | 0.7     | 0.9%          |
| Model 2                              | 0.98(0.85,1.14) | 0.8           | 0.99(0.99,1.00)     | 0.9     | 0.7%          |
| Prevalent diabetes mellitus          |              |                |                     |         |
| Model 1                              | 1.35(1.18,1.54) | <0.001        | 1.00(0.99,1.01)     | 0.1     | 5.6%          |
| Model 2                              | 1.39(1.15,1.68) | <0.001        | 1.00(0.98,1.02)     | 0.8     | 0.3%          |
| BMI                                  |              |                |                     |         |
| Model 1                              | 1.03(1.02,1.04) | <0.001        | 1.00(1.00,1.01)     | 0.06    | 2.7%          |
| Model 2                              | 1.03(0.95,1.10) | 0.5           | 1.00(0.99,1.00)     | 0.9     | 0.1%          |
| **Fibrinogen**                       |              |                |                     |         |
| Smoking Status*                      |              |                |                     |         |
| Model 1                              | 1.09(1.05,1.12) | <0.001        | 1.01(1.01,1.02)     | <0.001  | 15.0%         |
| Model 2                              | 1.09(1.05,1.31) | <0.001        | 1.01(1.00,1.01)     | 0.01    | 5.7%          |
| Current Smoking                      |              |                |                     |         |
| Model 1                              | 1.16(1.02,1.31) | 0.01          | 1.01(0.99,1.03)     | 0.02    | 9.4%          |
| Model 2                              | 1.18(1.05,1.33) | <0.01         | 1.01(0.99,1.02)     | 0.2     | 5.9%          |
| Ever Smoking                         |              |                |                     |         |
| Model 1                              | 1.13(1.03,1.25) | 0.01          | 1.02(1.00,1.03)     | 0.01    | 13.4%         |
| Model 2                              | 1.12(1.02,1.24) | 0.02          | 1.00(0.99,1.01)     | 0.5     | 3.4%          |
| Alcohol Intake*                      |              |                |                     |         |
| Model 1                              | 0.96(0.94,0.98) | <0.01         | 0.99(0.99,0.99)     | <0.01   | 20.1%         |
| Model 2                              | 0.97(0.94,0.99) | 0.02          | 0.99(0.99,0.99)     | <0.01   | 15.7%         |
| Prevalent Hypertension               |              |                |                     |         |
| Model 1                              | 1.16(1.06,1.28) | <0.01         | 1.05(1.03,1.07)     | <0.01   | 27.6%         |
| Model 2                              | 1.12(1.07,1.29) | 0.1           | 1.01(0.99,1.02)     | 0.2     | 8.4%          |
| Antihypertensive drug use            |              |                |                     |         |
| Model 1                              | 1.13(1.02,1.25) | 0.02          | 1.05(1.03,1.07)     | 0.02    | 30.5%         |
| Model 2                              | 1.03(0.84,1.26) | 0.8           | 1.01(0.97,1.06)     | 0.5     | 18.6%         |
| Prevalent diabetes mellitus          |              |                |                     |         |
| Model 1                              | 1.47(1.29,1.68) | <0.001        | 1.09(1.05,1.12)     | <0.001  | 25.9%         |
| Model 2                              | 1.37(1.17,1.61) | <0.001        | 1.03(0.97,1.10)     | 0.4     | 7.5%          |
| BMI                                  |              |                |                     |         |
| Model 1                              | 1.02(1.01,1.03) | <0.001        | 1.01(1.01,1.01)     | <0.001  | 29.3%         |
| Model 2                              | 1.01(1.00,1.02) | 0.05          | 1.01(1.01,1.01)     | <0.001  | 24.8%         |
risk of MI among users of oral contraceptives has been reported28. Yet, we did not observe significant associations between exogenous hormone use or the biomarkers and MI risk in our study.

Given the range of significant associations between cardiovascular risk factors and the biomarkers of vascular injury outlined above, we carried out mediation analyses to investigate whether associations between established CVD risk factors and MI risk could be mediated by the biomarkers. While the mediation analyses using the method proposed by VanderWeele indicated no significant mediation effect of P-Selectin in the associations between cardiovascular risk factors and MI risk, our results suggest that fibrinogen may mediate the relationships between smoking, alcohol consumption, and BMI and MI risk. Overall, none of the six tested biomarkers in addition to fibrinogen in our study was significantly associated with MI risk over time upon multivariable adjustment. However, there were no significant differences between extreme quartiles, and we cannot rule out that the observed linear trend is a statistical artefact, since other previous studies have reported no associations between this biomarker and MI risk39. Thus, the markers may reflect haemostatic alterations due to known CVD risk factors, but do not seem to exert independent or indirect pathophysiological effects in MI development.

Our study had several limitations. We measured plasma biomarkers from blood samples obtained at a single time point, i.e. at the baseline of the EPIC-Heidelberg Study. However, all biomarkers had shown good biological reproducibility prior to the present analyses38, and regression dilution may not explain the lack of longitudinal associations with MI risk. Although our analyses have shown several statistically significant associations between biomarkers of vascular injury and established cardiovascular risk factors, the magnitude of most associations was rather low. Another limitation was that baseline data on the type of exogenous hormones used and measured blood pressure were not available for our analyses. Due to the lack of intact platelets, we did not have the opportunity to obtain routine parameters of platelet function and turnover, which would have been of interest in the present study. Lastly, the EPIC-Heidelberg cohort consists of rather health-conscious individuals compared to the German general population, and associations between biomarkers and CVD risk factors may be more pronounced in populations including participants with more unfavourable risk factor profiles, even though our sample did include meaningful proportions of heavy smokers, drinkers etc. to guarantee sufficient contrast for etiological analyses. The strengths of this study comprise the relatively large number of MI cases, the high quality and specificity (MI and not CHD) of case ascertainment, the prospective population-based set-up, the comprehensive set of biomarkers, and the wide range of available covariates.

Conclusion
Taken together, our results suggest that biomarkers of vascular injury and platelet activation (E-Selectin, P-Selectin, TPO, TM, ICAM3, and GPIIb/IIIa) are associated with established CVD risk factors, particularly sex, alcohol consumption, diabetes, and exogenous hormone use. At the same time, they may not constitute independent risk factors for MI.

Methods
Study population. The EPIC-Heidelberg cohort included 25,540 participants aged from 35–65 years, who were recruited between 1994–1998 from the local general population31,32. At baseline, detailed questionnaire and interview assessments on diet, lifestyle factors, drug use (including oral contraceptive use and hormone replacement therapy after menopause), and health status were carried out, and anthropometric measurements were taken. Moreover, blood samples were collected, processed and stored for later measurement of biomarkers. Participants have been followed-up by active and passive procedures since baseline1. The Ethics Committee of the Heidelberg University Hospital approved the study and all participants gave written informed consent. All methods were performed in accordance with the relevant guidelines and regulations. The present analyses on plasma biomarkers and MI risk were conducted using a case-cohort data analysis design33. The study population consisted of a random sub-cohort (n = 2,418) and all incident cases of MI (n = 369) that occurred until December 31st 2006 (Supplementary Fig. 1). From the n = 598 primarily identified incident cases of MI, 413 were validated (n = 185 falsified cases), n = 35 were excluded due to unavailability of blood samples, and n = 9 were excluded due to prevalent stroke at baseline.

Ascertainment of Incident Myocardial Infarction. Incident cases of MI were identified based on self-reports from questionnaires (during three waves of follow-up, with response rates of > 95%), death certificates obtained via linkages with mortality registries, and record linkages with local university hospitals34. All cases were then validated by a trained study physician (MLG) using patient records. For 311 (84.3%) of the cases, a definitive validation by diagnostic records based on criteria of the World Health Organization, i.e. clinical presentation, electrocardiogram and cardiac biomarkers35 was possible, while 58 cases (15.7%) could only be validated by records of general practitioners, which did not include diagnostic details (see Supplementary Fig. 1). An exclusion of these 58 cases from statistical models only very marginally affected the results (data not shown), which was why we decided to include them in our risk analyses. The international classification of diseases (ICD-10) system was used to classify incident MI (ICD-10 I21).

Laboratory Methods. Baseline blood samples were processed in citrate plasma, buffy coat, erythrocyte and serum samples, which were then aliquoted into plastic straws and stored in liquid nitrogen (−196 °C). A single plasma straw per participant was retrieved and stored in freezers at − 80 °C for four weeks between samples retrieval and biomarker measurements. Aliquots were thawed prior to analyses of E-Selectin, P-Selectin, TM, TPO, ICAM3, GPIIb/IIIa, and fibrinogen. The “Quiplex SQ 120” instrument from Meso Scale Discoveries...
(MSD Maryland, USA) was used to measure E-Selectin, P-Selectin, TM, and ICAM3 ("human vascular injury kit 1") multiplex assay kit from MSD) as well as TPO ("U-Plex TPO Assay" kit from MSD) by electrochemiluminescence immunoassays (ECLIA). GPIIb/IIIa and fibrinogen levels were measured by enzyme-linked immunosorbent assays (ELISA) using the essay kits "ab108851" from Abcam (Cambridge, UK) and "KA0475" from Abnova (Heidelberg, Germany). Kits came all from the same production lots. Samples from cases and non-cases were randomly assigned to the batches to minimize possible differential misclassification, and case status was blinded to the laboratory personnel. Each batch contained two quality control (QC) plasma samples in duplicate in order to monitor the validity of the measurements within and across the batches. Within-batch coefficients of variation (CVs) [between batch CVs] were 3.6% [10.6%] for E-Selectin, 3.3% [9.1%] for P-Selectin, 3.8% [10.1%] for TM, 4.6% [19.5%] for TPO, 7.5% [20.1%] for ICAM3, 5.5% [46.9%] for GPIIb/IIIa, and 5.7% [8.5%] for fibrinogen. Batch-standardization of biomarker levels for multivariable regression analyses (see statistical analyses section) was performed by using the batch mean-centering method. However, given the random allocation of samples from cases and non-cases on analytical batches, statistical analyses based on batch-standardized and non-batch-standardized biomarker levels showed highly similar results (data not shown).

Before the start of the present project, we tested the biological reproducibility of biomarker concentrations over one year in a sub-sample of 78 EPIC-Heidelberg participants, who were invited to the study center for a sub-study on body composition between 2010 and 2013. All biomarkers showed a good one-year reproducibility, with Spearman’s correlation coefficients of 0.80 (P-Selectin), 0.73 (TPO) 0.63 (TM), and 0.51 (GPIIb/IIIa). For the present study we further tested the one-year reproducibility of E-Selectin and ICAM3 in the same sub-sample, and obtained Spearman’s correlation coefficients of 0.88 for E-Selectin and 0.69 for ICAM3.

**Statistical Analyses.** Continuous variables are described as median (interquartile range, IQR) and categorical variables as numbers (percentages). All plasma batch-standardized biomarkers were log2 transformed to better approximate a normal distribution, and standardized (mean of 0 and standard deviation [SD] of 1), in order to facilitate comparisons of hazard ratios per SD across biomarkers. We further categorized batch-standardized biomarker levels by quartiles (using cut-off points based on the sex-specific distribution in the sub-cohort) for cross-sectional and longitudinal regression analyses. Correlations between the biomarkers were evaluated by Spearman's coefficients. Cross-sectional associations between biomarkers and categorical covariates were evaluated by Generalized Linear Models adjusted for age and sex (model 1) and additionally adjusting for established cardiovascular risk factors (model 2). The maximum percentage of missing values in the covariates was 7%. These were multiply imputed under the missing at random (MAR) assumption, using fully conditional (FCS) algorithm, with the number of imputations set to 5.

We used Cox proportional hazards regression models with the weighting method for case-cohort designs as suggested by Prentice to calculate hazard rate ratios (HR) and 95% confidence intervals (CI)37. Each plasma biomarker was analysed as an individual risk factor for incident MI. We left-truncated at the time of blood sampling, and all participants wereensored at the time of MI diagnosis, death, loss of follow-up, or the end of the study follow-up (31st December 2006), whichever occurred first. Covariates were chosen based on literature review. Model 1 was adjusted for age and sex. Model 2 was additionally adjusted for other cardiovascular risk factors i.e. height (cm), waist circumference (cm), alcohol consumption (g/day in the 1-year period before baseline), smoking status (never, past quit, ≥10 years ago, quitted <10 years ago, current >15 cigarettes/day, ≥15 cigarettes/day), hypertension (yes/no), anti-hypertensive drug use (yes/no), diabetes mellitus (yes/no), C-Reactive Protein (CRP), total cholesterol, HDL-cholesterol, education (primary, secondary, university), and physical activity (Cambridge Index; inactive/moderately inactive and moderately inactive/active)38. Extended correlation tests based on Schoenfeld residuals indicated no violations of the proportional hazards assumption. Potential effect modifications of sex and age were tested including a multiplicative term into the Cox regression models. Furthermore, we used the method proposed by VanderWeele to perform statistical analyses on causal mediation4. A two-sided p-value of less than 0.05 denoted statistical significance, and statistical analyses were conducted in R (version 3.4.3) and SAS 9.4 (Cary, NC) for Windows.

**Data Availability** Data are made available by the corresponding author upon reasonable request.

**References**

1. AISBL, E. H. N. European CVD Statistics 2017, http://www.ehnheart.org/index.php (2018).
2. Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. *Circulation* **105**, 1135–1143 (2002).
3. Jennings, L. K. Role of platelets in atherothrombosis. *Am J Cardiol* **103**, 4A–10A, https://doi.org/10.1016/j.amjcadio.2008.11.017 (2009).
4. Ferroni, P. et al. Biomarkers of platelet activation in acute coronary syndromes. *Thromb Haemost* **108**, 1109–1123, https://doi.org/10.1078/1072-8634-00905 (2012).
5. Danesh, J., Collins, R., Appleby, P. & Peto, R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. *JAMA* **279**, 1477–1482 (1998).
6. Danesh, J. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* **350**, 1387–1397, https://doi.org/10.1056/NEJMoa032804 (2004).
7. Danesh, J. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. *BMJ* **321**, 199–204 (2000).
8. Jones, D. A., Abbassi, O., Mcintire, L. V., McEver, R. P. & Smith, C. W. P-selectin mediates neutrophil rolling on histamine-stimulated endothelial cells. *Biophys J* **65**, 1560–1569, https://doi.org/10.1016/S0006-3495(93)81195-0 (1993).
9. McEver, R. P. Selectins: lectins that initiate cell adhesion under flow. *Curr Opin Cell Biol* **14**, 581–586 (2002).
10. Ley, K., Luddanna, C., Cybulsky, M. I. & Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nat Rev Immunol* **7**, 678–689, https://doi.org/10.1038/nri2156 (2007).
11. Jackson, S. P. Arterial thrombosis–insidious, unpredictable and deadly. Nat Med 17, 1423–1436, https://doi.org/10.1038/nm.2515 (2011).

12. Quinn, M. J., Plow, E. F. & Topol, E. J. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 106, 379–385 (2002).

13. Esmon, C. T. et al. Inflammation, sepsis, and coagulation. Haematologica 84, 254–259 (1999).

14. Hitchcock, I. S. & Kaushansky, K. Thrombopoietin from beginning to end. Br J Haematol 165, 259–268, https://doi.org/10.1111/bjh.12772 (2014).

15. Larsen, S. B., Grove, E. L., Hvas, A. M. & Kristensen, S. D. Platelet turnover in stable coronary artery disease - influence of thrombopoietin and low-grade inflammation. PLoS One 9, e85566, https://doi.org/10.1371/journal.pone.0085566 (2014).

16. Canepanero, M. R., Sanchez-Mateos, P., del Pozo, M. A. & Sanchez-Madrid, F. ICAM-3 regulates lymphocyte morphology and integrin-mediated T cell interaction with endothelial cell and extracellular matrix ligands. The Journal of cell biology 127, 867–878 (1994).

17. Torr, E. E. R. et al. Apoptotic cell-derived ICAM-3 promotes both macrophage chemotraction to and tethering of apoptotic cells. Cell death and differentiation 19, 671–679, https://doi.org/10.1038/cdd.2011.167 (2012).

18. Valeri, L. & VanderWeele, T. J. SAS macro for causal mediation analysis with survival data. Epidemiology 26, e23–e24, https://doi.org/10.1097/EDE.0000000000000253 (2015).

19. Thorand, B. et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 26, 398–405, https://doi.org/10.1161/ATVHA.106.362949 (2006).

20. Thorand, B. et al. Association of cardiovascular risk factors with markers of endothelial dysfunction in middle-aged men and women. Results from the MONICA/KORA Augsburg Study. Thromb Haemost 95, 134–141 (2006).

21. Thorand, B., Baumert, J., Herder, C., Meisinger, C. & Koenig, W. Soluble thrombomodulin as a predictor of type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1988-1998. Diabetologia 50, 545–548, https://doi.org/10.1007/s00125-006-0568-x (2007).

22. Bieilinski, S. J. et al. P-selectin and subclinical and clinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 240, 3–9, https://doi.org/10.1016/j.atherosclerosis.2015.02.036 (2015).

23. Kaptoge, S. et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 166, 867–879, https://doi.org/10.1093/aje/kwm191 (2007).

24. Tolstrup, J. S., Gronbaek, M. & Nordestgaard, B. G. Alcohol intake, myocardial infarction, biochemical risk factors, and alcohol dehydrogenase genotypes. Circulation. Cardiovascular genetics 2, 507–514, https://doi.org/10.1161/circgenetics.109.873604 (2009).

25. Wood, A. M. et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599,912 current drinkers in 83 prospective studies. Lancet. London (England), 1999, 1513–1523, https://doi.org/10.1016/s0140-6736(18)30134-x (2018).

26. Ylikorkala, O., Evo, S., Valimaki, M. & Titinen, A. Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women. Fertil Steril 80, 541–543 (2003).

27. Mueck, A. O. & Seeger, H. Biochemical markers surrogating on vascular effects of sex steroid hormones. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology 22, 163–173, https://doi.org/10.1080/09513590600629258 (2006).

28. Roach, R. E. et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. The Cochrane database of systematic reviews, Cd011054, https://doi.org/10.1002/14651858.CD011054.pub2 (2015).

29. Malik, I. et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358, 971–976, https://doi.org/10.1016/s0140-6736(01)07362-8 (2001).

30. Graf, M. E. et al. Biological reproducibility of circulating P-Selectin, Thrombopoietin, GPIIb/IIIa and Thrombomodulin over one year. Clin Biochem 50, 942–946, https://doi.org/10.1016/j.clinbiochem.2017.05.017 (2017).

31. Boeijing, H., Korfmann, A. & Bergmann, M. M. Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab 43, 205–215, https://doi.org/10.1159/000012787 (1999).

32. Boeijing, H., Warenordorff, J. & Becker, N. EPIC-Germany—A source for studies into diet and risk of chronic diseases. European Investigation into Cancer and Nutrition. Ann Nutr Metab 43, 195–204, https://doi.org/10.1159/000012786 (1999).

33. Kulathinal, S., Karvanen, J., Saarela, O. & Kuulasmaa, K. Case-cohort design in practice - experiences from the MORGAM Project. Eur J Epidemiol 31, 168–174 (2002).

Acknowledgements
The EPIC-Heidelberg study was sponsored by the German Federal Ministry of Education and Research (Grant No. 01ER0809) and the German Cancer Research Center (DKFZ). Funding [for grant number 2015/1418] was obtained from World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant program and from the Helmholtz Association of German Research Centres (Portfolio Theme: Metabolic Dysfunction). Funding agencies had no role in designing and interpreting the present study.

Author Contributions
T.K. designed the analysis plan with support from L.P.B., D.S., P.B., M.H., M.E.G. and R.K. M.E.G. and T.J. carried out the laboratory measurements; M.K. and M.L.G. carried out the case validation; L.P.B. performed the statistical analyses, with support from S.G.M., A.H., M.E.G. and D.S. L.P.B. drafted the first version of the manuscript, T.K. revised it; L.P.B. and T.K. had the primary responsibility for the final content of the manuscript; T.K. and R.K. acquired the data and obtained the funding; all authors contributed to the interpretation of data, revised the manuscript, and approved its final version.
**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-38259-y.

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019